TRIM22 and chronic myelogenous leukemia, BCR-ABL1 positive: Besides, TRIM22 knockdown inhibited the activation of PI3K/Akt/mTOR pathway by decreasing the level of the phosphorylated form p‐Akt and p‐mTOR in chronic myeloid leukemia (Li et al., 2018).